Lexiscan Clinical Trials In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted ...
SILVER SPRING, Md. -- Two agents used in cardiac nuclear stress tests may carry a greater risk of heart attack and death than previously believed, the FDA said Wednesday. "When reported, these adverse ...
WASHINGTON, Nov. 20 (UPI) -- The U.S. Food and Drug Administration warns doctors of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents. The cardiac ...
The chemical agents used for cardiac stress tests that look for signs of heart disease may in fact trigger heart attacks in patients, the Food and Drug Administration warned Wednesday. The side effect ...
Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac nuclear stress tests of patients with signs or ...
The US Food and Drug Administration (FDA) has issued a new warning that Lexiscan (regadenoson) and Adenoscan (adenosine), two intravenously-administered drugs used during cardiac nuclear stress tests, ...
FDA: Stress Test Agents Linked to Possible Heart Attack, Death The FDA is warning healthcare professionals of the rare but serious risk of heart attack and death associated with the use of Lexiscan ...
Please provide your email address to receive an email when new articles are posted on . The FDA has issued a safety announcement warning health care professionals of rare but serious risk for MI and ...
Doctors are being warned that two drugs used in cardiac nuclear stress tests can cause heart attacks and death in patients, the U.S. Food and Drug Administration says. These rare but serious events ...
DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...
Lexiscan Clinical Trials In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted ...
PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results